Company Overview

Company name: Connecticut Pharmaceutical Solutions
Description: Developer of marijuana therapies intended to improve health and wellness in the State of Connecticut. The company specialize in supercritical fluid extraction, solvent-based and solventless extraction, and other techniques for the production of waxes, concentrates, kief, and hash which are further refined and formulated to produce vaping liquids, oils, dabs, and tinctures to give patients a vaping product that contains a high concentration of the flower’s native terpenes, with the added benefit of no carrier ingredients, helping patients to address the symptoms of cancer, AIDS, multiple sclerosis, glaucoma, epilepsy, and other conditions.
Year founded: 2013
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
City: Portland
State: Connecticut
Country: United States
Region: Americas

Financial Highlights

Start up capital raised (USD Million):
Business status: Generating Revenue
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Enterprise value:
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period:
Financing Status: The company was acquired by Tuatara Capital through an LBO on August 22, 2018 for an undisclosed sum.
Number of active investors:
Profile last updated: 08-Sep-2018
Last known valuation:
Last known valuation date: